Watch RVMD. Know when insiders buy.
One email the day a filing lands. Free.
Work order
61
WATCH · insiders 25, shorts 96
Insiders, 90 days
−$41.3M
net selling · 0 buys, 31 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
1 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $45BP/E —DIV YIELD —FCF YIELD -2.74%REV TTM —NET INCOME −$1.8BNET CASH —52W 40.45 – 221.15SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$505.1M | −$644.4M | — | -3.06 | −$387.3M | $2.3M | −$389.6M | Aug 5 |
| Q1 2026 · Mar 31 | — | — | — | −$445.2M | −$453.8M | — | -2.29 | −$354.2M | $1.5M | −$355.7M | Aug 5 |
| Q4 2025 · Dec 31derived | — | — | — | −$361.6M | −$364.9M | — | -1.89 | −$274.2M | $1.9M | −$276.2M | Feb 25 |
| Q3 2025 · Sep 30 | — | — | — | −$315.3M | −$305.2M | — | -1.61 | −$207.3M | $3.3M | −$210.7M | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$264.7M | −$247.8M | — | -1.31 | −$221.8M | $7.5M | −$229.2M | Aug 5 |
| Q1 2025 · Mar 31 | — | — | — | −$240.8M | −$213.4M | — | -1.13 | −$194.4M | $3.3M | −$197.7M | Aug 5 |
| Q4 2024 · Dec 31derived | $0 | −100.0% | — | −$216.3M | −$194.6M | — | -1.13 | −$138.3M | $1.2M | −$139.5M | Feb 25 |
| Q3 2024 · Sep 30 | $0 | — | — | −$175.7M | −$156.3M | — | -0.94 | −$130.4M | $3.5M | −$133.9M | Nov 5 |
| Q2 2024 · Jun 30 | $0 | — | — | −$156.6M | −$133.2M | — | -0.81 | −$128.2M | $2.4M | −$130.6M | Nov 5 |
| Q1 2024 · Mar 31 | $0 | — | — | −$140.9M | −$116M | — | -0.70 | −$160.6M | $3.2M | −$163.7M | Nov 5 |
| Q4 2023 · Dec 31derived | $742K | — | — | −$180M | −$161.5M | — | -1.21 | −$120.6M | $2.3M | −$122.9M | Feb 25 |
| Q3 2023 · Sep 30 | $0 | — | — | −$123.2M | −$108.4M | — | -0.99 | −$100.5M | $2.5M | −$103M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $0 | — | −$1.2B | −$1.1B | — | -5.95 | −$897.7M | $16M | −$913.7M | — | — |
| FY2024 · to Dec 31 | $0 | — | −$689.5M | −$600.1M | — | -3.58 | −$557.4M | $10.3M | −$567.7M | — | — |
| FY2023 · to Dec 31 | $11.6M | — | −$487.2M | −$436.4M | -3768.3% | -3.86 | −$350.6M | $7.7M | −$358.3M | — | — |
| FY2022 · to Dec 31 | $35.4M | — | −$258.3M | −$248.7M | -703.0% | -3.08 | −$224.4M | $10.8M | −$235.2M | — | — |
| FY2021 · to Dec 31 | $29.4M | — | −$188M | −$187.1M | -636.6% | -2.57 | −$147.2M | $6.5M | −$153.7M | — | — |
| FY2020 · to Dec 31 | $43M | — | −$110.7M | −$108.2M | -251.6% | -2.01 | −$100.1M | $2.9M | −$103M | — | $0 |
Every number comes from Revolution Medicines, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.